Skip to main content
Erschienen in: Supportive Care in Cancer 12/2009

01.12.2009 | Original Article

An exploratory study on the Italian patients’ preferences regarding how they would like to be told about their cancer

verfasst von: Emanuela Mauri, Elena Vegni, Edoardo Lozza, Patricia A. Parker, Egidio A. Moja

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Goal

Major cross-cultural differences in truth-telling attitudes and practices have been demonstrated. Until recently, in Italy the doctor could conceal both diagnosis and prognosis to seriously ill patients out of beneficence. Signs of change have been reported, but the extent and way patients would be informed is still unknown. The aim of the study was to assess Italian patients’ preferences regarding how they would like to be told about their cancer and its treatment. We examined the factor structure of the Measure of Patients’ Preferences—Italian version (MPP-It) and whether demographical and medical variables were associated with the dimensions of patients’ preferences.

Materials and methods

Patients were invited to participate during a visit to the oncology department of the Lecco hospital (Italy) for chemotherapy or follow-up. An Italian version of the MPP-It was administered. Data were analyzed through a factor analysis.

Main results

A total of 210 cancer patients agreed to participate. Three main factors were identified: (1) Information (Talking About the Disease). Items in this factor were concerned with the dialogue about the disease and treatment options; (2) Support (The Emotional World of the Patient). These items referred to the supportive and relational aspects of the physician–patient encounter; (3) Care (The Ideal Doctor). These items related to the patients’ desires about the doctor’s personal attributes.

Conclusions

The first two factors, information and support, were comparable to those of similar American and Asian studies. The study suggests a cross-cultural uniformity among cancer patients who appreciate the informative and clearness of the communication aspects as being primarily important, while also giving high points to relationship aspects. The third factor appears unique to the Italian context.
Literatur
1.
Zurück zum Zitat Anderlik MR, Pentz RD, Hess KR (2000) Revisiting the truth-telling debate: a study of disclosure practices at a major cancer center. J Clin Ethics 11:251–259PubMed Anderlik MR, Pentz RD, Hess KR (2000) Revisiting the truth-telling debate: a study of disclosure practices at a major cancer center. J Clin Ethics 11:251–259PubMed
2.
Zurück zum Zitat Cavanna L, Anselmi E, Lazzaro A, Seghini P, Di Nunzio C, Dallanegra L, Monfredo M (2007) Cancer diagnosis disclosure in a northern Italian hospital. Report on 312 consecutive cancer patients. Tumori 93:290–291PubMed Cavanna L, Anselmi E, Lazzaro A, Seghini P, Di Nunzio C, Dallanegra L, Monfredo M (2007) Cancer diagnosis disclosure in a northern Italian hospital. Report on 312 consecutive cancer patients. Tumori 93:290–291PubMed
4.
Zurück zum Zitat Costantini M, Marasso G, Montella M, Borgia P, Cecioni R, Beccaro M, Sguazzotti E, Bruzzi P (2006) Diagnosis and prognosis disclosure among cancer patients. Results from an Italian mortality follow-back survey. Ann Oncol 17:853–859. doi:10.1093/annonc/mdl028 CrossRefPubMed Costantini M, Marasso G, Montella M, Borgia P, Cecioni R, Beccaro M, Sguazzotti E, Bruzzi P (2006) Diagnosis and prognosis disclosure among cancer patients. Results from an Italian mortality follow-back survey. Ann Oncol 17:853–859. doi:10.​1093/​annonc/​mdl028 CrossRefPubMed
5.
7.
Zurück zum Zitat Fontanesi S, Goss C, Rimondini M (2007) How to involve patients in the decision making process. Recenti Prog Med 98:611–618PubMed Fontanesi S, Goss C, Rimondini M (2007) How to involve patients in the decision making process. Recenti Prog Med 98:611–618PubMed
8.
Zurück zum Zitat Fujimori M, Akechi T, Morita T, Inagaki M, Azikuki N, Sakano Y, Uchitomi Y (2007) Preferences of cancer patients regarding the disclosure of bad news. Psychooncology 16:573–581. doi:10.1002/pon.1093 CrossRefPubMed Fujimori M, Akechi T, Morita T, Inagaki M, Azikuki N, Sakano Y, Uchitomi Y (2007) Preferences of cancer patients regarding the disclosure of bad news. Psychooncology 16:573–581. doi:10.​1002/​pon.​1093 CrossRefPubMed
9.
Zurück zum Zitat Grassi L, Girali T, Messina EG, Magnani K, Valle E, Cartei G (2000) Physicians’ attitudes to and problems with truth-telling to cancer patients. Support Care Cancer 8:40–45PubMed Grassi L, Girali T, Messina EG, Magnani K, Valle E, Cartei G (2000) Physicians’ attitudes to and problems with truth-telling to cancer patients. Support Care Cancer 8:40–45PubMed
10.
Zurück zum Zitat The Italian Group for the Evaluation of Outcomes in Oncology (IGEO) (1999) Awareness of disease among Italian cancer patients: Is there a need for further improvement in patient information? Ann Oncol 10:1095–1100. doi:10.1023/A:1017278918524 CrossRef The Italian Group for the Evaluation of Outcomes in Oncology (IGEO) (1999) Awareness of disease among Italian cancer patients: Is there a need for further improvement in patient information? Ann Oncol 10:1095–1100. doi:10.​1023/​A:​1017278918524 CrossRef
13.
Zurück zum Zitat Mobeireek AF, Al-Kassimi F, Al-Zahrani K, Al-Shimemeri A, Al-Damegh S, Al-Amoudi O, Al-Eithan S, Al-Ghamdi B, Gamal-Eldin M (2008) Information disclosure and decision-making: the Middle East versus the Far East and the West. J Med Ethics 34:225–229. doi:10.1136/jme.2006.019638 CrossRefPubMed Mobeireek AF, Al-Kassimi F, Al-Zahrani K, Al-Shimemeri A, Al-Damegh S, Al-Amoudi O, Al-Eithan S, Al-Ghamdi B, Gamal-Eldin M (2008) Information disclosure and decision-making: the Middle East versus the Far East and the West. J Med Ethics 34:225–229. doi:10.​1136/​jme.​2006.​019638 CrossRefPubMed
15.
Zurück zum Zitat Parker PA, Baile WF, de Moor C, Lenzi R, Kudelka AP, Cohen L (2001) Breaking bad news about cancer: patients’ preferences for communication. J Clin Oncol 19:2049–2056PubMed Parker PA, Baile WF, de Moor C, Lenzi R, Kudelka AP, Cohen L (2001) Breaking bad news about cancer: patients’ preferences for communication. J Clin Oncol 19:2049–2056PubMed
17.
Zurück zum Zitat Searight HR, Gafford J (2005) Cultural diversity at the end of life: issues and guidelines for family physicians. Am Fam Physician 71:515–522PubMed Searight HR, Gafford J (2005) Cultural diversity at the end of life: issues and guidelines for family physicians. Am Fam Physician 71:515–522PubMed
Metadaten
Titel
An exploratory study on the Italian patients’ preferences regarding how they would like to be told about their cancer
verfasst von
Emanuela Mauri
Elena Vegni
Edoardo Lozza
Patricia A. Parker
Egidio A. Moja
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0621-7

Weitere Artikel der Ausgabe 12/2009

Supportive Care in Cancer 12/2009 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.